KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide corresponding to residues 11 through 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide with broad anti-inflammatory and immunomodulatory activity. KPV retains most of the anti-inflammatory capacity of the full hormone while lacking the pigmentary effects conferred by the N-terminal His-Phe-Arg-Trp pharmacophore sequence.

The dominant cellular mechanism identified in intestinal epithelial and immune cells does not require classical melanocortin receptor binding. In those tissues, KPV is transported intracellularly by PepT1 (SLC15A1), a di/tripeptide transporter constitutively expressed in the small intestine and upregulated in inflamed colonic tissue during IBD. Once inside the cell, KPV stabilizes IkBa, the inhibitory protein that sequesters the transcription factor NF-kB in the cytoplasm. By preventing nuclear translocation of the p65RelA subunit — through interaction with the importin-alpha3 binding site on p65RelA — KPV suppresses transcription of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-8. The peptide also inhibits the MAPK (MAP kinase) inflammatory signaling cascade at nanomolar concentrations.

In human bronchial epithelial cells, parallel work demonstrated that KPV suppresses NF-kB-driven IL-8 secretion and matrix metalloproteinase-9 activity through direct IkBa stabilization, while full-length alpha-MSH acts through a distinct apical MC3R-dependent pathway. This mechanistic divergence indicates KPV accesses intracellular targets independently of G-protein-coupled receptor activation.

• Antimicrobial activity documented in vitro may be mediated partly through elevation of intracellular cyclic AMP, which was partially reversed by the adenylyl cyclase inhibitor dideoxyadenosine.

All published evidence for KPV as a therapeutic agent derives from in vitro cell studies and preclinical animal experiments. No controlled human clinical trials have been conducted or registered as of mid-2026, and the FDA has stated it lacks human exposure data for this compound.

The landmark study by Dalmasso et al. (Gastroenterology, 2008; PMID 18061177) demonstrated that KPV at nanomolar concentrations inhibited NF-kB and MAPK activation in human intestinal epithelial cell lines and macrophages challenged with pro-inflammatory stimuli. In a dextran sodium sulfate (DSS)-induced colitis mouse model (n=5 per group), oral KPV at 100 micromolar in drinking water reduced histological colitis scores and suppressed mRNA expression of pro-inflammatory cytokines. Parallel results were obtained in a TNBS-induced colitis model (n=10 per group).

Subsequent preclinical work focused on improving intestinal delivery. A 2016 study in Molecular Therapy reported that KPV loaded into hyaluronic acid-functionalized poly(lactic-co-glycolic acid) nanoparticles (approximately 272 nm) significantly reduced colitis severity in DSS-treated mice, with preferential uptake in inflamed colonic tissue.

In airway research, Land (International Journal of Physiology, Pathophysiology and Pharmacology, 2012; PMID 22837805) demonstrated dose-dependent suppression of NF-kB, IL-8, eotaxin, and MMP-9 by KPV in human bronchial epithelial cells stimulated with TNF-alpha and respiratory syncytial virus.

For skin, Sung et al. (Tissue Cell, 2025; PMID 40073467) reported that KPV at 50 micrograms/mL restored cell viability and reduced IL-1beta secretion in human keratinocytes damaged by PM10 fine particulate matter, with associated suppression of ROS production and caspase-1 activation.

Cutuli et al. (Journal of Leukocyte Biology, 2000; PMID 10670585) demonstrated in vitro that KPV and full-length alpha-MSH significantly inhibited Staphylococcus aureus colony formation and reduced Candida albicans viability and germ tube formation at concentrations spanning the picomolar to micromolar range, while concurrently enhancing — rather than suppressing — neutrophil killing activity.

A 2023 narrative review in Cells (Gravina et al.; PMID 37508552) concluded that melanocortin-derived peptides including KPV represent mechanistically plausible candidates for IBD pharmacotherapy, while acknowledging that human translation has not occurred.

Typical dosage: 500-1000 mcg (daily).

No dosage protocol for KPV has been established through controlled human clinical trials. The values below reflect preclinical experimental concentrations and anecdotal prescriber practice only.

In murine colitis models, effective oral administration used approximately 100 micromolar KPV in drinking water; in vitro biological activity was demonstrated at concentrations as low as 10 nanomolar. These values cannot be directly converted to human doses without pharmacokinetic data that does not presently exist.

In compounding and wellness settings, where KPV has been prescribed off-label by licensed clinicians operating under specific regulatory exemptions, reported protocols include:

• Subcutaneous injection: approximately 0.5 mg to 2 mg once daily, self-injected into the abdomen, thigh, or upper arm. Cycles typically reported as 4 to 12 weeks.

• Oral capsule (targeting gut-localized effects): approximately 0.5 mg to 10 mg per day. Oral delivery is considered plausible because PepT1 is expressed in intestinal epithelium, though systemic oral bioavailability of intact KPV is uncertain given luminal protease activity.

• Topical formulations (gel or cream): applied to affected skin areas in concentrations that have not been standardized in any study.

KPV has a molecular weight of approximately 342 Da and does not require the reconstitution process used for larger lyophilized peptides.

This information is provided for educational purposes only, reflects preclinical data and anecdotal clinical practice, and does not constitute medical advice. KPV is not FDA-approved for any indication and should not be used outside a supervised clinical context with full informed consent.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No peer-reviewed clinical or preclinical study has examined KPV in formal combination with any other peptide or drug. All combination rationales described below are based on anecdotal prescriber and community practice only and have not been tested for pharmacodynamic interactions, additive toxicity, or clinical efficacy.

BPC-157 (body protection compound) is the most frequently reported co-administration with KPV in gut-focused protocols. The proposed rationale is mechanistic complementarity: BPC-157 is claimed to promote intestinal mucosal healing and angiogenesis via VEGF pathways, while KPV acts on the NF-kB inflammatory cascade. This pairing appears in some compounding clinic offerings under proprietary stack names but has no controlled experimental basis.

TB-500 (thymosin beta-4 N-terminal fragment) is included in extended recovery stacks on the basis of its purported actin-sequestering and cell-migration-promoting properties, intended to address tissue remodeling during chronic inflammation.

GHK-Cu (glycine-histidine-lysine-copper) is added by some practitioners for proposed collagen synthesis and wound-healing support, particularly in skin-focused formulations.

The mechanistic rationale for each individual component is plausible in isolation, but pharmacodynamic interactions, combined safety, and any synergistic or antagonistic effects among these peptides remain entirely uninvestigated in the published literature.

KPV is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed KPV from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place KPV on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026. PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very well-tolerated

Formal human safety data for KPV is absent. The U.S. Food and Drug Administration has stated that it "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans." On this basis, the FDA classified KPV as a Category 2 substance in its compounding framework, restricting its use in compounded preparations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The agency has indicated KPV is among compounds under review for potential reclassification, though no reclassification had occurred as of the time of writing.

In published animal experiments — the longest of which ran approximately 12 weeks — no significant hepatotoxicity, nephrotoxicity, dose-limiting organ dysfunction, or behavioral abnormalities were documented at therapeutic-range doses.

Based on anecdotal prescriber reporting only (no systematic pharmacovigilance data exists), the most commonly noted adverse effects are:

• Mild injection site redness or discomfort with subcutaneous use • Gastrointestinal discomfort at higher oral doses • Transient headache

Persons with active malignancy should exercise particular caution: alpha-MSH-derived peptides interact with melanocortin receptors expressed on some tumor cell types, and the implications of KPV exposure in oncology patients are uninvestigated. Use during pregnancy and lactation is contraindicated by precaution due to the complete absence of safety data in those populations.

Research-grade KPV obtained from unregulated commercial sources carries additional risks related to purity, endotoxin contamination, immunogenicity from process impurities, and mislabeling. A favorable preclinical safety profile in rodents does not constitute evidence of safety in humans.